Taken together, these findings indicated that the combination of oncolytic virotherapy and immune checkpoint blockers such as anti‐PD‐1 or anti‐PD‐L1 could be effective in cancer treatment via suppressing virus‐induced inhibitory molecules, the release of tumor‐specific antigens, and the infiltration of CD4+ and CD8+ T cells at the tumor site. Here, CD8A is linked to neoplasm.